The story of Viagra, initially marketed by copyright, presents a complex case study for backers considering the pharmaceutical sector. Although its initial success and generation of countless in earnings , the exclusivity lapse has opened the floodgates for generic medications, greatly eroding income opportunities. This shift raises questions about